North China Pharmaceutical Co Ltd (600812) — Cash Flow Reinvestment Rate
North China Pharmaceutical Co Ltd (600812) has a Cash Flow Reinvestment Rate of 0.85x as of September 2025, reinvesting CN¥144.38 Million (capex CN¥144.38 Million ) from operating cash flow of CN¥170.24 Million. Check 600812 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
North China Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2000–2025)
Historical reinvestment intensity for North China Pharmaceutical Co Ltd across 22 annual periods. Explore how much of North China Pharmaceutical Co Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for North China Pharmaceutical Co Ltd (2000–2025)
Year-by-year capital reinvestment analysis for North China Pharmaceutical Co Ltd. For live market cap and broader valuation context, see market cap of North China Pharmaceutical Co Ltd.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.66x | CN¥781.54 Million | CN¥1.18 Billion | CN¥542.01 Million | ▼ -44.0% |
| 2024 | 1.19x | CN¥1.46 Billion | CN¥1.23 Billion | CN¥784.22 Million | ▼ -19.3% |
| 2023 | 1.47x | CN¥1.50 Billion | CN¥1.02 Billion | CN¥623.04 Million | ▲ +167.5% |
| 2022 | 0.55x | CN¥551.58 Million | CN¥1.00 Billion | CN¥549.58 Million | ▼ -26.8% |
| 2021 | 0.75x | CN¥787.50 Million | CN¥1.05 Billion | CN¥547.50 Million | ▼ -44.1% |
| 2020 | 1.34x | CN¥1.01 Billion | CN¥752.15 Million | CN¥1.01 Billion | ▲ +51.7% |
| 2019 | 0.88x | CN¥648.46 Million | CN¥732.97 Million | CN¥645.97 Million | ▲ +34.6% |
| 2018 | 0.66x | CN¥509.13 Million | CN¥774.33 Million | CN¥506.64 Million | ▼ -68.5% |
| 2017 | 2.09x | CN¥599.69 Million | CN¥287.25 Million | CN¥399.69 Million | ▼ -55.0% |
| 2015 | 4.64x | CN¥567.81 Million | CN¥122.50 Million | CN¥367.81 Million | ▲ +62.5% |
| 2014 | 2.85x | CN¥258.30 Million | CN¥90.56 Million | CN¥258.30 Million | ▼ -42.9% |
| 2011 | 4.99x | CN¥1.14 Billion | CN¥227.60 Million | CN¥1.14 Billion | ▲ +1279.5% |
| 2009 | 0.36x | CN¥366.10 Million | CN¥1.01 Billion | CN¥366.10 Million | ▲ +184.8% |
| 2008 | 0.13x | CN¥138.00 Million | CN¥1.09 Billion | CN¥138.00 Million | ▼ -14.1% |
| 2007 | 0.15x | CN¥98.27 Million | CN¥664.37 Million | CN¥98.27 Million | ▲ +70.8% |
| 2006 | 0.09x | CN¥51.72 Million | CN¥597.12 Million | CN¥51.72 Million | ▼ -89.5% |
| 2005 | 0.82x | CN¥184.67 Million | CN¥224.17 Million | CN¥184.67 Million | ▼ -26.6% |
| 2004 | 1.12x | CN¥348.50 Million | CN¥310.39 Million | CN¥348.50 Million | ▲ +47.2% |
| 2003 | 0.76x | CN¥442.77 Million | CN¥580.32 Million | CN¥442.77 Million | ▲ +150.8% |
| 2002 | 0.30x | CN¥224.68 Million | CN¥738.50 Million | CN¥224.68 Million | ▼ -41.7% |
| 2001 | 0.52x | CN¥191.79 Million | CN¥367.28 Million | CN¥191.79 Million | ▼ -28.5% |
| 2000 | 0.73x | CN¥97.52 Million | CN¥133.49 Million | CN¥97.52 Million | — |